KraS inhibitor adagrasib treated non-small cell lung cancer with no disease progression in 83% of the responding patients

Aggregate efficacy data from Phase I/Ib and Phase II clinical trials show that in patients with advanced non-small cell lung cancer (NSCLC) previously treated, the use of Mirati Therapeutics' adagrasib monotherapy achieved an objective response rate (ORR) of 45%. charles Baum, chief executive of the
, said the findings "demonstrate the enduring anti-tumor activity of adagrasib in patients with NSCLC, giving new hope to patients with KRAS G12C mutations."
" Photo Source: Amgen Adgrasib is a select inhibitor of the KRAS G12C, optimized for extended half-life.
83% of NSCLC respondents had no progression I/Ib and Phase II studies that included 51 patients with advanced NSCLC who received a median of two systemic treatments, all of which had received platinum-based chemotherapy, and 92% of patients who had previously received anti-PD-1/L1 inhibitors.
Adgrasib's treatment achieved 45% ORR, the disease control rate (DCR) reached 96%.
83% of the patients who responded did not experience disease progression.
NSCLC patients with late KRAS G12C plus STK11 mutations, the results showed that 9 out of 14 patients achieved ORR.
addition, in a patient with nSCLC who had been brain-transferred, adagrasib reduced tumor volume by 67% and the brain metastasis tumor was removed.